Method to predict or monitor the response of a patient to an erbb receptor drug
AssigneeAstraZeneca UK Limited
InventorsKazuto Nishio, Hideharu Kimura, Kazuo Kasahara
Life of this patent
Estimating the term…
Abstract
The invention provides a method of detecting ErbB receptor mutations comprising the steps of providing a bio-fluid sample from a patient; extracting DNA from said sample; and screening said DNA for the presence of one or more mutations that alter tyrosine kinase activity in the receptor.
Claims32
A method for detecting one or more mutations in an ErbB receptor for predicting the response of a patient to an ErbB receptor drug comprising the steps of:
- (a) providing a bio-fluid sample from a patient;
- (b) extracting DNA from said sample;
- and
- (c) screening said DNA for the presence of one or more mutations in the receptor.
A composition comprising a first primer pair which is used to detect the wild type allele and a second primer pair which is used to detect the mutant allele of an ErbB receptor wherein one primer of each pair further comprises:
- (a) a primer with a terminal 3′ nucleotide that is allele specific for a particular mutation;
- and
- (b) possible additional mismatches at the 3′ end of the primer;
- (c) a single molecule or nucleic acid duplex probe containing both a primer sequence and a further sequence specific for the target sequence;
- (d) a fluorescent reporter dye attached to the 5′ end in close proximity with a quencher molecule within said single molecule or nucleic acid duplex;
- (e) one or more non-coding nucleotide residues at one end of said probe;
- (f) wherein said reporter dye and quencher molecule become separated during amplification of the target sequence.
Use of a primer specific for an ErbB receptor in an assay conducted with a bio-fluid for predicting the response of a patient to an ErbB drug.
Use of a primer specific for an ErbB receptor in the manufacture of a composition for testing a bio-fluid for predicting the response of a patient to an ErbB drug.
Dependencies are inferred from the claim text.